Company Description
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders.
The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation.
The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance.
The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016.
Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 2, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Shao-Lee Lin |
Contact Details
Address: 40 Guest Street Boston, Massachusetts 02135 United States | |
| Phone | 617 949 2680 |
| Website | cuebiopharma.com |
Stock Details
| Ticker Symbol | CUE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645460 |
| CUSIP Number | 22978P205 |
| ISIN Number | US22978P2056 |
| Employer ID | 47-3324577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shao-Lee Lin M.D., Ph.D. | President, Chief Executive Officer and Director |
| Lucinda Warren | Principal Fin and Accounting Off. and Chief Financial & Business Officer |
| Colin G. Sandercock J.D., MSE | Senior Vice President of Intellectual Property |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Rodolfo Jose Chaparro Ph.D. | Co-Founder |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific and Clinical Advisory Board |
| Sumita Ray J.D. | Chief Legal and Compliance Officer and Corporate Secretary |
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 17, 2026 | EFFECT | Notice of Effectiveness |
| Jun 3, 2026 | 8-K | Current Report |
| Jun 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 3, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 2, 2026 | 8-K | Current Report |
| May 21, 2026 | DEF 14A | Other definitive proxy statements |
| May 14, 2026 | 8-K | Current Report |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | D | Notice of Exempt Offering of Securities |